Cargando…

Broad-spectrum in vitro antiviral activity of ODBG-P-RVn: an orally-available, lipid-modified monophosphate prodrug of remdesivir parent nucleoside (GS-441524)

The intravenous administration of remdesivir for COVID-19 confines its utility to hospitalized patients. We evaluated the broad-spectrum antiviral activity of ODBG-P-RVn, an orally available, lipid-modified monophosphate prodrug of the remdesivir parent nucleoside (GS-441524) against viruses that ca...

Descripción completa

Detalles Bibliográficos
Autores principales: Lo, Michael K., Shrivastava-Ranjan, Punya, Chatterjee, Payel, Flint, Mike, Beadle, James R., Valiaeva, Nadejda, Schooley, Robert T., Hostetler, Karl Y., Montgomery, Joel M., Spiropoulou, Christina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cold Spring Harbor Laboratory 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8366795/
https://www.ncbi.nlm.nih.gov/pubmed/34401879
http://dx.doi.org/10.1101/2021.08.06.455494
_version_ 1783738952912470016
author Lo, Michael K.
Shrivastava-Ranjan, Punya
Chatterjee, Payel
Flint, Mike
Beadle, James R.
Valiaeva, Nadejda
Schooley, Robert T.
Hostetler, Karl Y.
Montgomery, Joel M.
Spiropoulou, Christina
author_facet Lo, Michael K.
Shrivastava-Ranjan, Punya
Chatterjee, Payel
Flint, Mike
Beadle, James R.
Valiaeva, Nadejda
Schooley, Robert T.
Hostetler, Karl Y.
Montgomery, Joel M.
Spiropoulou, Christina
author_sort Lo, Michael K.
collection PubMed
description The intravenous administration of remdesivir for COVID-19 confines its utility to hospitalized patients. We evaluated the broad-spectrum antiviral activity of ODBG-P-RVn, an orally available, lipid-modified monophosphate prodrug of the remdesivir parent nucleoside (GS-441524) against viruses that cause diseases of human public health concern, including SARS-CoV-2. ODBG-P-RVn showed 20-fold greater antiviral activity than GS-441524 and had near-equivalent activity to remdesivir in primary-like human small airway epithelial cells. Our results warrant investigation of ODBG-P-RVn efficacy in vivo.
format Online
Article
Text
id pubmed-8366795
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Cold Spring Harbor Laboratory
record_format MEDLINE/PubMed
spelling pubmed-83667952021-08-17 Broad-spectrum in vitro antiviral activity of ODBG-P-RVn: an orally-available, lipid-modified monophosphate prodrug of remdesivir parent nucleoside (GS-441524) Lo, Michael K. Shrivastava-Ranjan, Punya Chatterjee, Payel Flint, Mike Beadle, James R. Valiaeva, Nadejda Schooley, Robert T. Hostetler, Karl Y. Montgomery, Joel M. Spiropoulou, Christina bioRxiv Article The intravenous administration of remdesivir for COVID-19 confines its utility to hospitalized patients. We evaluated the broad-spectrum antiviral activity of ODBG-P-RVn, an orally available, lipid-modified monophosphate prodrug of the remdesivir parent nucleoside (GS-441524) against viruses that cause diseases of human public health concern, including SARS-CoV-2. ODBG-P-RVn showed 20-fold greater antiviral activity than GS-441524 and had near-equivalent activity to remdesivir in primary-like human small airway epithelial cells. Our results warrant investigation of ODBG-P-RVn efficacy in vivo. Cold Spring Harbor Laboratory 2021-08-10 /pmc/articles/PMC8366795/ /pubmed/34401879 http://dx.doi.org/10.1101/2021.08.06.455494 Text en https://creativecommons.org/publicdomain/zero/1.0/This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available for use under a CC0 license (https://creativecommons.org/publicdomain/zero/1.0/) .
spellingShingle Article
Lo, Michael K.
Shrivastava-Ranjan, Punya
Chatterjee, Payel
Flint, Mike
Beadle, James R.
Valiaeva, Nadejda
Schooley, Robert T.
Hostetler, Karl Y.
Montgomery, Joel M.
Spiropoulou, Christina
Broad-spectrum in vitro antiviral activity of ODBG-P-RVn: an orally-available, lipid-modified monophosphate prodrug of remdesivir parent nucleoside (GS-441524)
title Broad-spectrum in vitro antiviral activity of ODBG-P-RVn: an orally-available, lipid-modified monophosphate prodrug of remdesivir parent nucleoside (GS-441524)
title_full Broad-spectrum in vitro antiviral activity of ODBG-P-RVn: an orally-available, lipid-modified monophosphate prodrug of remdesivir parent nucleoside (GS-441524)
title_fullStr Broad-spectrum in vitro antiviral activity of ODBG-P-RVn: an orally-available, lipid-modified monophosphate prodrug of remdesivir parent nucleoside (GS-441524)
title_full_unstemmed Broad-spectrum in vitro antiviral activity of ODBG-P-RVn: an orally-available, lipid-modified monophosphate prodrug of remdesivir parent nucleoside (GS-441524)
title_short Broad-spectrum in vitro antiviral activity of ODBG-P-RVn: an orally-available, lipid-modified monophosphate prodrug of remdesivir parent nucleoside (GS-441524)
title_sort broad-spectrum in vitro antiviral activity of odbg-p-rvn: an orally-available, lipid-modified monophosphate prodrug of remdesivir parent nucleoside (gs-441524)
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8366795/
https://www.ncbi.nlm.nih.gov/pubmed/34401879
http://dx.doi.org/10.1101/2021.08.06.455494
work_keys_str_mv AT lomichaelk broadspectruminvitroantiviralactivityofodbgprvnanorallyavailablelipidmodifiedmonophosphateprodrugofremdesivirparentnucleosidegs441524
AT shrivastavaranjanpunya broadspectruminvitroantiviralactivityofodbgprvnanorallyavailablelipidmodifiedmonophosphateprodrugofremdesivirparentnucleosidegs441524
AT chatterjeepayel broadspectruminvitroantiviralactivityofodbgprvnanorallyavailablelipidmodifiedmonophosphateprodrugofremdesivirparentnucleosidegs441524
AT flintmike broadspectruminvitroantiviralactivityofodbgprvnanorallyavailablelipidmodifiedmonophosphateprodrugofremdesivirparentnucleosidegs441524
AT beadlejamesr broadspectruminvitroantiviralactivityofodbgprvnanorallyavailablelipidmodifiedmonophosphateprodrugofremdesivirparentnucleosidegs441524
AT valiaevanadejda broadspectruminvitroantiviralactivityofodbgprvnanorallyavailablelipidmodifiedmonophosphateprodrugofremdesivirparentnucleosidegs441524
AT schooleyrobertt broadspectruminvitroantiviralactivityofodbgprvnanorallyavailablelipidmodifiedmonophosphateprodrugofremdesivirparentnucleosidegs441524
AT hostetlerkarly broadspectruminvitroantiviralactivityofodbgprvnanorallyavailablelipidmodifiedmonophosphateprodrugofremdesivirparentnucleosidegs441524
AT montgomeryjoelm broadspectruminvitroantiviralactivityofodbgprvnanorallyavailablelipidmodifiedmonophosphateprodrugofremdesivirparentnucleosidegs441524
AT spiropoulouchristina broadspectruminvitroantiviralactivityofodbgprvnanorallyavailablelipidmodifiedmonophosphateprodrugofremdesivirparentnucleosidegs441524